WVE (WAVE Life Sciences) Accounts Payable & Accrued Expense : $17.69 Mil (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is WAVE Life Sciences Accounts Payable & Accrued Expense?

WAVE Life Sciences's quarterly accounts payable & accrued expense increased from Mar. 2024 ($14.65 Mil) to Jun. 2024 ($21.39 Mil) but then declined from Jun. 2024 ($21.39 Mil) to Sep. 2024 ($17.69 Mil).

WAVE Life Sciences's annual accounts payable & accrued expense increased from Dec. 2021 ($11.96 Mil) to Dec. 2022 ($22.18 Mil) but then declined from Dec. 2022 ($22.18 Mil) to Dec. 2023 ($15.60 Mil).

WAVE Life Sciences Accounts Payable & Accrued Expense Historical Data

The historical data trend for WAVE Life Sciences's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WAVE Life Sciences Accounts Payable & Accrued Expense Chart

WAVE Life Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

16.60

16.76

11.96

22.18

15.60

WAVE Life Sciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															16.78	15.60	14.65	21.39	17.69

WAVE Life Sciences Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

WAVE Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (NAS:WVE) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

1U5:Germany

Address

Marina One East Tower, 7 Straits View No. 12-00, Singapore, SGP, 018936

Website

https://www.wavelifesciences.com

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Executives

Paul Bolno	director, officer: See Remarks	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Chris Francis	officer: See Remarks	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Plc Glaxosmithkline	10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Kyle Moran	officer: See Remarks	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Chandra Vargeese	officer: See Remarks	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE, CAMBRIDGE MA 02138
Michael A. Panzara	officer: Franchise Lead, Neurology	733 CONCORD AVENUE, CAMBRIDGE MA 02138
Ra Capital Management, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Aik Na Tan	director	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
David G Gaiero	officer: Interim CFO	733 CONCORD AVENUE, C/O WAVE LIFE SCIENCES USA, INC., CAMBRIDGE MA 02138
Gregory L. Verdine	director	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE, CAMBRIDGE MA 02138
Heidi L Wagner	director	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Amy Pott	director	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Mark Corrigan	director